Last reviewed · How we verify
TIO/OLO
TIO/OLO is a fixed-dose combination of tiotropium (a long-acting muscarinic antagonist) and olodaterol (a long-acting beta-2 agonist) that works synergistically to relax and open airways in chronic obstructive pulmonary disease.
TIO/OLO is a fixed-dose combination of tiotropium (a long-acting muscarinic antagonist) and olodaterol (a long-acting beta-2 agonist) that works synergistically to relax and open airways in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | TIO/OLO |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | Muscarinic M3 receptor and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium blocks muscarinic M3 receptors on airway smooth muscle to provide sustained bronchodilation, while olodaterol activates beta-2 adrenergic receptors to further relax airways. Together, these complementary mechanisms provide dual bronchodilation with improved lung function and symptom control in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
- Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
- Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
- Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)
- Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
- An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIO/OLO CI brief — competitive landscape report
- TIO/OLO updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI